Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Stephanie Sutton was an assistant editor at Pharmaceutical Technology Europe.

Articles

As part of an ongoing collaboration into tabletting science, I Holland and the UK's University of Nottingham have launched a two-year programme to investigate the cause of tabletting sticking.

Research Project Targets Tablet Sticking

Amy Ritter was Scientific Editor, BioPharm International.

Ranbaxy Laboratories announced that beginning in March 2012, the first shipments of atorvastatin, the generic version of Pfizer's Lipitor, had been sent to US markets from its new Mohali manufacturing facility located in Punjab, India.

Ranbaxy Begins Shipping Generic Lipitor From Indian Facility

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

On Mar. 29, 2012, the Generic Pharmaceutical Association reiterated its call for Congress to move forward with user-fee proposals for generic drugs and biosimilar products.

GPhA Urges Congress to Move Ahead on Generic-Drug and Biosimilar User Fees

In Part III of a three-part article, the authors examine various degradation routes of APIs, impurities arising from interactions in formulations, metabolite impurities, various analytical methods to measure impuritie, and ways to control impurities.

Evaluating Impurities in Drugs (Part III of III)

With financing constrained, biotechnology firms must find ways to sustain innovation.

A Sustainable Biotech Path

How to use geographic diversification and legacy technology transfers to avoid product shortages.

Managing Product Supply Risks

In our tablet coating process, we are losing up to 15% of our coating solution in each processing run. What can we do to prevent this problem in order to reduce waste and increase our cost efficiency?

Reducing Waste in Tablet Coating

On Mar. 7, 2012, GE Healthcare announced an agreement to acquire Xcellerex, a supplier of manufacturing technologies for the biopharmaceutical industry, for an undisclosed amount.

GE Healthcare to Acquire Xcellerex

AstraZeneca Files Suit Against FDA; Pfizer, Biocon Terminate Biosimilar Alliance; and More.